Enzymotec Ltd. (ENZY: Quote), a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced Thursday that it has appointed Steve Dubin as Chairman of its board of directors, effective January 1, 2014.
The company also announced that it has appointed Yoav Doppelt as Vice Chairman of the board. Doppelt has served as Chairman of Enzymotec's board of directors since October 2011 and as a director since 2001. He will continue to be an actively involved board member and will assist Dubin during the transition process.
Steve Dubin has served as Vice Chairman of Enzymotec's board of directors since April 2013. Since November 2011, Dubin has been a Principal in SDA Ventures LLC.
Dubin also acts as a Senior Advisor to Paine & Partners, LLC. From 2006 until its acquisition by Royal DSM N.V. in February 2011, Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He also served as President of DSM's Nutritional Lipids Division immediately after DSM's acquisition of Martek and as a Senior Advisor to DSM Nutritional Products from 2011 through October 2012.
Having joined Martek in 1992, he held various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, as well as President of Martek from 2003 to 2006.
Dubin is a co-founder and co-manager of a Maryland-based, angel-investing club. Dubin currently serves as a member of the board of several privately held companies, including The Brain Center, LLC, MyCell Technologies and its subsidiary Oceans Omega LLC, and Alcresta, Inc. Prior to that, he was a member of the board of directors of Scerene Healthcare Inc.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org